MPO China First Domestic Bipolar System for Hemiarthroplasty Receives NMPA Approval, Completing the Domestic Primary Arthroplasty Product Line

The Bipolar Easy™ Hemiarthroplasty System (Bipolar Easy™), a proprietary product developed and produced by Suzhou MicroPort® OrthoRecon Co., Ltd., a subsidiary of MPO China, recently received the registration certificate issued by the National Medical Products Administration (NMPA), making it the first domestic hemiarthroplasty system by MPO China to receive marketing approval.

Featuring with a bipolar design, Bipolar Easy™ can more effectively reduce the incidence of post-operative joint pain and allow for greater range of motion for patients, as compared with using systems with unipolar hemiarthroplasty design. The system is compatible with the Goral™ Total Hip Arthroplasty System independently developed and manufactured by MPO China, and it completes and supplements the line of domestic primary hip arthroplasty systems to meet the clinical needs of elderly patients with femoral neck fracture.

Zixin Weng, President of MPO China, said, “Following the launch of domestic total knee replacement systems SoSuperior™ and Aspiration™ last year and Goral™ Total Hip Arthroplasty System this year, the recent marketing approval of Bipolar Easy™ Hemiarthroplasty Bipolar System marks the completion of domestic primary arthroplasty product line of MPO China.”
**speX Support Catheter Obtains NMPA Registration Certificate**

The speX Support Catheter distributed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently received a registration certificate from the National Medical Products Administration (NMPA) for use in China.

The speX Support Catheter provides access to peripheral vascular lesions. Used in conjunction with a guidewire, it is able to pass narrow occlusion in the peripheral vasculature, particularly useful in facilitating the opening of extended occlusion in the lower extremities.

Zhenghua Miao, President of Endovastec™, has said, “Endovastec™ is committed to providing patients with integrated solutions for peripheral vascular interventions, and the speX Support Catheter follows a series of products, including drug-coated balloon dilatation catheters, peripheral vascular stent systems and peripheral vascular balloon dilatation catheters, improving the treatment of patients around the world. The registration of the speX Support Catheter further enriches the product line of Endovastec™ and improves the company’s product portfolio in the field of peripheral vascular interventions.”
MicroPort® EP PathBuilder™ IceMagic™ Steerable Introducer Obtains Important NMPA Registration Approval


The approved PathBuilder™ IceMagic™ Steerable Introducer is the first domestic product of its kind for use in conjunction with cryoablation balloons. It is also the first product in the cryoablation portfolio of MicroPort® EP to receive registration approval from NMPA. The certification of this product marks the further enrichment of MicroPort® EP’s product line in the field of complex arrhythmias, providing doctors and patients with diversified treatment options ranging from cryoablation to radiofrequency ablation.
Endovastec™ Reewarm™
PTX Drug Coated Balloon
PTA Catheter Receives
EU CE Marking Certification

The Reewarm™ PTX Drug Coated Balloon PTA Catheter (“Reewarm™ PTX DCB Catheter”), developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”), has received CE marking certification in the European Union.

“We previously received CE marking certification for the Minos® Abdominal Aortic Stent-Graft, the Hercules™ Low-Profile Thoracic Stent-Graft, and many other products,” said Zhenghua Miao, President of Endovastec™. “The certification of the Reewarm™ PTX DCB Catheter further strengthens our product portfolio in the EU and international markets.”
MicroPort® NeuroTech Bridge™
Vertebral Drug-Eluting Stent Approved for Launch in China

The Bridge™ Vertebral Drug-Eluting Stent, developed by Shanghai MicroPort NeuroTech Co., Ltd. (MicroPort® NeuroTech), received a registration certificate issued by China’s National Medical Products Administration (NMPA) on December 17, 2020 for the treatment of symptomatic vertebral artery stenosis.

The approved Bridge™ Vertebral Drug-Eluting Stent features a unique drug delivery design in which the drug is loaded only inside the grooves on the stent surface facing the vessel wall, allowing for faster endothelialization and reduced thromboembolic events and restenosis. The approval further completes the neurointerventional product line of MicroPort® NeuroTech.
Endovastec™ Castor™
Branched Aortic Stent-Graft System Enters First Overseas Market

The first implantation of the Castor™ Branched Aortic Stent-Graft and Delivery System ("Castor™"), developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™"), was successfully completed in Poland.

Castor™ is the world’s first stent-graft system for simultaneous aorta and aortic arch repair through minimally invasive treatment. Its unique unibody structure can adapt to a variety of arch anatomies and allows one-off access and release, which ensures safe and convenient reconstruction of the left subclavian artery while reducing the incidence of endoleak and provides long-term stability. Castor™ has entered more than 400 hospitals in China since its launch, and its innovative features have won recognition by clinical experts.

Zhenghua Miao, President of Endovastec™, said, “The completion of the first clinical implantation of Castor™ in Poland is of great importance to its further promotion in overseas markets. It will lay the foundation for the product’s use in clinical applications in more countries overseas.”
**Daylily™ Single-Use Sterile Embryo Transfer Catheter from HorizonMedical™ Approved for Use in China**

Daylily™ single-use sterile embryo transfer catheter (‘Daylily™ embryo transfer catheter’), developed by Shanghai Horizon Medical Co., Ltd. (HorizonMedical™), has recently been registered with Shanghai Municipal Drug Administration. The Daylily™ embryo transfer catheter is to be used for gentle implantation of embryos during in vitro fertilization (IVF) procedures. Available in different sizes, this product provides doctors with a wide selection to fit their usage habits and patients’ different conditions.

As a subsidiary of MicroPort® and focusing on medical solutions in the field of assisted reproduction, HorizonMedical™ develops, manufactures, sells and provides technical support to medical products used in all stages of an assisted reproduction cycle. This includes egg retrieval and fertilization, freezing and storage of gametes and embryos, cultivation and processing of gametes and embryos, as well as embryo implantation. HorizonMedical™ currently has other products approved for sale in China, including the Lotus® single-use sterile egg retrieval needles.
Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System Registration Approved in Korea

The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), a proprietary product of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort*), has received registration approval from the Ministry of Food and Drug Safety of Korea (MFDS).

While retaining some features of Firehawk™ stent—such as targeted drug-release—Firehawk Liberty™ uses an innovative stent balloon technology to optimize expansion performance, thus further optimizing the crossability and vessel wall apposition.

The approval of the Firehawk Liberty™ further expands the coronary intervention product line of MicroPort* in South Korea. It also increases the influence and market share of MicroPort* in the local market, as the Firehawk™ Rapamycin Target Eluting Coronary Stent System, the Firefighter™, the Firefighter™ NC PTCA Balloon Dilatation Catheter and other MicroPort* products continue to gain trust and acceptance of surgeons and patients in South Korea. In the future, MicroPort* will continue to deepen its reach in the Korean market and provide quality, inclusive and integrated solutions for patients in the country.
MicroPort CRM Initiates a Clinical Trial for Breakthrough Innovative Left Ventricular Lead Axone™

MicroPort® Cardio Rhythm Management (CRM) has announced the first enrollment in the Astral-4LV clinical trial to evaluate the safety and efficiency of Axone™, a breakthrough innovative quadripolar left ventricular lead. Axone™ is designed for use in heart failure patients with Cardiac Resynchronisation Therapy (CRT) indications that require the implantation of a CRT pacemaker (CRT-P) or CRT implantable defibrillator (CRT-D).

Astral-4LV is a prospective, single arm, multicenter clinical trial that will enroll 152 patients at 20 centres in France, Germany, Italy, Netherlands, Portugal, Spain, and Austria. The primary objectives are the related complication free rate and the success rate of left ventricular pacing. A secondary objective of the Astral-4LV study evaluates the success rate of a bi-zone left ventricular pacing. The study data will be used to support CE marking of Axone™. The primary endpoints will be evaluated at 6-month post-implantation and the patients will be followed for 4 years.

The Axone Project has received funding from the European Union’s Horizon 2020 research and innovation program. MicroPort CRM is leading the project in collaboration with Heraeus GmbH, Germany, the University Hospital of Rouen, France, and Maastricht University, Netherlands.
MicroPort® MedBot’s Toumai™ Endoscopic Surgical System Completes First Clinical Trial of Robot-Assisted Partial Nephrectomy

The Toumai™ Endoscopic Surgery Robotic System (Toumai™), a proprietary product of Shanghai MicroPort MedBot (Shanghai) Co., Ltd. (MicroPort® MedBot), completed the first robot-assisted partial nephrectomy (RAPN) procedure at the Zhejiang Provincial People’s Hospital. This first RAPN surgery marked a new step forward in its clinical research.

Prof. Zhang evaluated the performance of Toumai™ after the surgery, stating, “The advantages of the Toumai™ is that it enables doctors to complete tumor removal and renal suturing more quickly and efficiently during RAPN surgeries. With 18 minutes of thermal ischemia duration and less than 10ml of bleeding, the operation showed that the Toumai™ is fully comparable to its overseas competitors in terms of smooth running and duration of the operation,” said Prof. Zhang.

The Toumai™ is well suited for a wide spectrum of urological applications, particularly a range of reconstructive procedures including partial nephrectomy. Currently, steady progress is being made in conducting clinical trials and commercialization of the Toumai™.
MicroPort® MedBot’s Toumai™ Endoscopic Surgical System Completes First Robot-Assisted Extraperitoneal Radical Prostatectomy

The Toumai™ Endoscopic Surgery Robotic System (Toumai™), a proprietary product of Shanghai MicroPort MedBot (Shanghai) Co., Ltd. (MicroPort® MedBot), completed the first robot-assisted extraperitoneal radical prostatectomy. Director Jianming Guo, Prof. Shuai Jiang and Prof. Zhibing Xu from Department of Urology of the Zhongshan Hospital Affiliated to Fudan University led the team.

Dr. Chao He, President of MicroPort® MedBot, said, “The successful completion of the first extraperitoneal radical prostatectomy fully demonstrated the technical strength and clinical value of the Toumai™ Endoscopic Robot in performing complex and difficult urological surgeries.”
MedBot’s Toumai™ Endoscopic Robot Completes First Partial Nephrectomy through Retroperitoneal Approach

The Toumai™ Endoscopic Surgery Robotic System (Toumai™ Endoscopic Robot), a proprietary product of Shanghai MicroPort MedBot (Shanghai) Co., Ltd. (MicroPort® MedBot), completed the first partial nephrectomy through retroperitoneal approach led by Prof. Jianming Guo, Director of Department of Urology of the Zhongshan Hospital Affiliated to Fudan University.

Commenting after the surgery, Prof. Guo said, “The dexterity of the robotic wrist of Toumai™ allows for flexible manipulations within the limits of the narrow space of the retroperitoneal approach. The 3D vision ensures a clear view that is conducive to visualizing complex and delicate operations. The partial nephrectomy was performed without event, which is a validation that Toumai™ is capable of performing operations of this kind.”

The procedure marks the first robot-assisted retroperitoneal approach to partial nephrectomy performed by Toumai™. It is an important clinical breakthrough in complicated cases of urological surgery, which follows on from the first use in a radical prostatectomy and partial nephrectomy completed in China.
MicroPort® MedBot’s Toumai™ Endoscopic Robot Combined with Intraoperative Ultrasound Completes Partial Nephrectomy for Completely Endophytic Renal Tumor

The Toumai™ Endoscopic Surgery Robotic System (Toumai™ Endoscopic Robot), a proprietary product of Shanghai MicroPort MedBot (Shanghai) Co., Ltd. (MicroPort® MedBot), a Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) subsidiary, has now enabled the successful completion of a complex partial nephrectomy for renal tumor. A team led by Dr. Wei Xue, Head of the Department of Urology, performed the operation, Renji Hospital affiliated to Shanghai Jiaotong University, and Prof. Jiahua Pan of the same department.

Director Xue commented after the operation, “The renal tumor in this case is completely endophytic, meaning it is completely surrounded by renal parenchyma. This made it difficult to precisely locate and identify the tumor boundary solely by visual observation. Hence, the operation needed to be performed in combination with intraoperative ultrasound. The excellent high-definition 3D field of view and smooth control performance of Toumai™ reliably guaranteed the successful completion of this complex partial nephrectomy for renal tumor.”
**First Clinical Implantation of MicroPort® Left Atrial Appendage Occluder Completed in Shanghai Chest Hospital**

The first clinical operation using the left atrial appendage occluder (LAAC) originally developed by Shanghai Micropor 佐心 (Zuoxin) Co., Ltd. (佐心™ Medical), a subsidiary of Shanghai Micropor Medical (Group) Co., Ltd. (“MicroPort™”), was completed at Shanghai Chest Hospital (SCH). The procedure was led by Director Ben He and Deputy Director Lixiang Jiang from Shanghai Chest Hospital and was streamed online.

The Left Atrial Appendage Closure System by 佐心™ Medical is the only semi-closed plug occluder which can push forward during releasing, made in China. It not only solves a clinical pain point of conventional plug occluders that require placing the sheath deep into the atrial appendage, but also significantly enhances the safety and operability of procedures.

As part of Microport™’s presence in the field of structural heart disease interventions, 佐心™ Medical has always been committed to helping patients with atrial fibrillation prevent the risk of stroke. Junfei Li, Executive Director of 佐心™ Medical said, “The first clinical implantation is an important milestone for us, and we look forward to more clinical data in the future so that we can benefit patients soon.”
MicroPort® Organizes “Belt and Road” International PCI Symposium at CIT Online 2020

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), together with experts from five countries, successfully organized CIT Online 2020, “Belt and Road” International PCI Symposium at the 10th China Interventional Therapeutics (CIT 2020). The symposium, which attracted an audience of nearly 8,000 experts and scholars from home and abroad, was part of the first-ever multi-session format at CIT 2020, held on December 5, 2020.

MicroPort® PCI products are now available in more than 30 countries along the “Belt and Road”, including Singapore, Malaysia, Indonesia and Thailand, providing integrated medical solutions for local doctors and patients in these countries. Responding to the situation that some Belt and Road countries are simply equipped with rudimentary medical equipment and have a shortage of surgeons with systematic education and training on minimally invasive surgery, MicroPort® has also launched a number of projects over the years to provide education and exchange opportunities for local doctors, disseminate the latest information and share clinical experiences.
MPO China Hosts
The 3rd SuperPATH™ Super+User (Better Together) Conference

MicroPort® Orthopedics (MPO) China recently hosted the 3rd SuperPATH™ Super+User (Better Together) Conference in Suzhou, China, where members of the “SuperPATH™ Super+User 100 Cases Club” gathered to exchange their insights on cutting-edge technologies and innovations in hip replacement.

Attendees also had an opportunity to explore and share knowledge on the concept and technical features of the MicroPort® hip arthroplasty technique SuperPATH™ in a variety of formats, including sessions on ‘Live Surgery’, ‘Panel Discussions’, ‘Guest Interviews’ and ‘Experience Sharing’. In particular, during the discussion on the SuperPATH™ technique, surgeons shared their practical experience and insights on technical challenges of the SuperPATH™ procedure in a special session titled ‘Face-to-Face with Newcomers and Veteran Super Users’.
MicroPort® NeuroTech Holds Launch Events for NUMEN™ Coil in Guangzhou and Hebei

MicroPort® NeuroTech brought together leading neurointerventional experts at the NUMEN™ Coil Launch Events in Guangzhou and Hebei to share the latest academic insights with the medical device community.

The Guangzhou launch event was moderated by Prof. Chuanzhi Duan from the Zhuijiang Hospital of Southern Medical University (SMU) and featured presentations by Prof. Guozhong Zhang from the Southern University of SMU and Prof. Xin Zhang from the Zhuijiang Hospital of SMU. The speakers shared their clinical experiences with the application of the NUMEN™ Coil in presentations titled “Clinical experience of NUMEN™ Coil applications”, and “Application of NUMEN™ Coil in the endovascular intervention of intracranial aneurysm: lessons learned”, respectively.

The Hebei Event was moderated by Prof. Jianliang Wu from the Second Hospital of Hebei Medical University (HMU), who fully recognized the performance of NUMEN™ Coil and hoped it could provide more treatment options for clinicians to safeguard the lives and wellbeing of patients.

Since its launch in October 2020, the NUMEN™ Coil has been highly recognized by physicians and experts for its stable positioning, dense embolization and excellent clinical performance. MicroPort® NeuroTech will continue to provide superior “all-in-one” cerebrovascular solutions to better safeguard the lives and wellbeing of patients.
MicroPort® Wins APQO
Global Performance Excellence Awards 2020

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) received the 2020 Global Performance Excellence Award (Best in Class) by Asia Pacific Quality Organization (APQO) on December 24, 2020. As the only Chinese company to receive this award in 2020, MicroPort® is delighted to win this international award for quality and make this the second consecutive award-winning year after getting the APQO Innovation Class Award in 2019.

In recent years, MicroPort® has been given a number of prominent awards for quality, including Shanghai Municipality Quality Gold Prize 2018, Shanghai Municipality Quality Benchmarks and the National Quality Benchmarks both in 2019 and 2020. Winning the APQO Global Performance Excellence Award is further testimony to MicroPort®’s continuous dedication to excellence in quality management.
HorizonMedical™ Selected as “National High-tech Enterprise”

Shanghai Horizon Medical Technology Co., Ltd. (Horizon Medical™) has been identified as a National High-tech Enterprise, this was announced recently in the “Notice on the Public Announcement of the Fourth Batch of High-tech Enterprises 2020” issued by the National Administration Office of High-tech Enterprise Recognition.

At present, the Lotus™ single lumen oocyte retrieval needle and Daylily™ embryo transfer catheter, two proprietary products developed by HorizonMedical™, have been approved for marketing and launched in China. The selection of HorizonMedical™ as a High-tech Enterprise signifies the recognition by the authorities on the company’s innovation system, independent innovation capability and comprehensive management strength. In the future, HorizonMedical™ will continue its efforts on innovative research and development, strengthen its core competitiveness, and reach out to more domestic and international markets. This enhances the commitment to becoming a total solutions provider of ART that will bring wider hope for more families and their chance to welcome new lives into the world.
Endovastec™ Accredited as “Shanghai Enterprise Technology Center”

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) was accredited as a “Shanghai Enterprise Technology Center” for its outstanding performance in developing technical talents and efforts in technological innovation, in the 2020 list of Municipal Enterprise Technology Centers in Shanghai (batch 26) recently released by Shanghai Municipal Economy and Information Technology Commission (SHEITC).

As a subsidiary of MicroPort Scientific Corporation (“MicroPort”), R&D innovation has always been a core driver of the rapid growth of Endovastec™, which established its own Technology Center in 2012, and developed full R&D capacity and a complete supply chain. As a result, it has been recognized as Pudong New Area Enterprise R&D Institution and MNC’s R&D Center. Endovastec™ holds a number of core technologies with independent intellectual property rights in the field of aortic and peripheral intervention. Its investment in R&D remains above industry average in recent years, and five products have entered the special approval procedure (“Green Path”) for innovative medical devices of the National Medical Products Administration (NMPA). Additionally, Endovastec™ has also established long-standing industry-academia-research innovation cooperation with a number of hospitals, universities and relevant institutions, which helps accelerate the commercialization of medical innovations.
Investor Newsletter
Issue 12 2020

For more information, please contact:

**Martin Sun**
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@micoport.com

**Leanne Li**
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@micoport.com